EuroIntervention 2023;19:256-266 published online ahead of print March 2023

Implantation of contemporary transcatheter aortic valves in small aortic annuli: the international multicentre TAVI-SMALL 2 registry

Pier Pasquale Leone[1,2,3], MD, MSc; Damiano Regazzoli[3], MD; Matteo Pagnesi[4], MD; Francesco Cannata[2,3], MD; Antonio Mangieri[3], MD; Thijmen W. Hokken[5], MD; Giuliano Costa[6], MD; Marco Barbanti[6], MD; Rui Teles[7], MD; Marianna Adamo[4], MD; Maurizio Taramasso[8], MD, PhD; Jörg Reifart[9], MD; Federico De Marco[10], MD; Francesco Giannini[11], MD; Faraj Kargoli[1], MD; Yohei Ohno[12], MD; Francesco Saia[13], MD; Andrea Buono[14], MD; Alfonso Ielasi[15], MD; Michele Pighi[16], MD; Mauro Chiarito[2,3], MD; Dario Bongiovanni[3], MD, PhD; Ottavia Cozzi[3], MD; Giulio Stefanini[2,3], MD, PhD, MSc; Flavio Ribichini[16], MD; Diego Maffeo[14], MD; Giuliano Chizzola[4], MD; Francesco Bedogni[11], MD; Won-Keun Kim[17], MD; Francesco Maisano[18], MD; Corrado Tamburino[7], MD; Nicolas M. Van Mieghem[5], MD, PhD; Antonio Colombo[2,3], MD; Bernhard Reimers[3], MD; Azeem Latib[1]*, MB, BCh; on behalf of the TAVI-SMALL Investigators.

The authors' affiliations can be found in the Appendix paragraph.

P.P. Leone and D. Regazzoli contributed equally to this manuscript and are joint first authors.

B. Reimers and A. Latib are joint last authors.

GUEST EDITOR: Franz-Josef Neumann, MD; *Department of Cardiology and Angiology II, University Heart Center Freiburg - Bad Krozingen, Bad Krozingen, Germany*

This paper also includes supplementary data published online at: https://eurointervention.pcronline.com/doi/10.4244/EIJ-D-22-00843

KEYWORDS

- aortic stenosis
- other

Abstract

Background: Treatment of aortic stenosis in patients with small annuli is challenging and can result in prosthesis-patient mismatch (PPM).

Aims: We aimed to compare the forward flow haemodynamics and clinical outcomes of contemporary transcatheter valves in patients with small annuli.

Methods: The TAVI-SMALL 2 international retrospective registry included 1,378 patients with severe aortic stenosis and small annuli (annular perimeter <72 mm or area <400 mm^2) treated with transfemoral self-expanding (SEV; n=1,092) and balloon-expandable valves (BEV; n=286) in 16 high-volume centres between 2011 and 2020. Analyses comparing SEV versus BEV and supra-annular (SAV; n=920) versus intra-annular valves (IAV; n=458) included inverse probability of treatment weighting (IPTW). The primary endpoints were the predischarge mean aortic gradient and incidence of severe PPM. The secondary endpoint was the incidence of more than mild paravalvular leak (PVL).

Results: The predischarge mean aortic gradient was lower after SAV versus IAV (7.8±3.9 vs 12.0±5.1; p<0.001) and SEV versus BEV implantation (8.0±4.1 vs 13.6±4.7; p<0.001). Severe PPM was more common with IAV and BEV when compared to SAV and SEV implantation, respectively, (8.8% vs 3.6%; p=0.007 and 8.7% vs 4.6%; p=0.041). At multivariable logistic regression weighted by IPTW, SAV protected from severe PPM regardless of its definition. More than mild PVL occurred more often with SEV versus BEV (11.6% vs 2.6%; p<0.001).

Conclusions: In small aortic annuli, implantation of SAV and SEV was associated with a more favourable forward haemodynamic profile than after IAV and BEV implantation, respectively. More than mild PVL was more common after SEV than BEV implantation.

**Corresponding author: Division of Cardiology, Montefiore Medical Center, 111 East 210th St., Bronx, NY 10467-2401, USA. E-mail: alatib@gmail.com*

SUBMITTED ON 26/09/2022 - REVISION RECEIVED ON 1st 20/11/2022 / 2nd 16/01/2023 - ACCEPTED ON 07/02/2023

DOI: 10.4244/EIJ-D-22-00843

Abbreviations

BEV balloon-expandable valve
EOA effective orifice area
IAV intra-annular valve
PPI permanent pacemaker implantation
PPM prosthesis-patient mismatch
PVL paravalvular leak
SAV supra-annular valve
SAVR surgical aortic valve replacement
SEV self-expanding valve
TAVI transcatheter aortic valve implantation

Introduction

Prosthesis-patient mismatch (PPM) is present when the effective area of a prosthetic valve inserted into a patient is inferior to that of a normal human valve; the haemodynamic consequence of a valve that is too small compared with the size of the patient's body is the generation of higher than expected transprosthetic gradients[1]. The incidence of PPM in patients undergoing transcatheter aortic valve implantation (TAVI) tends to be lower than in patients undergoing surgical aortic valve replacement (SAVR) and is reported to be between 6 and 46% for moderate PPM and between 0 and 15% for severe PPM[2,3]. In this setting, self-expanding valves (SEV) were shown to provide a more favourable forward haemodynamic profile compared to balloon-expandable valves (BEV), possibly thanks to the supra-annular leaflet position of most SEV[4,5]. A specific focus on patients with small aortic annuli stems from the fact that these patients showed the greatest benefit in terms of haemodynamics when treated with TAVI as compared to SAVR[6]. Similarly to the overall population, the haemodynamic advantage of TAVI in this subgroup of patients is particularly evident after SEV implantation[7,8]. Nonetheless, while evidence of the prognostic relevance of PPM after SAVR is well described, its clinical impact in patients undergoing TAVI remains debatable[2,5,9,10].

In this context, the relative performance of currently available transcatheter heart valves (THV) has not been investigated thoroughly. The aim of this study was to compare the haemodynamics and clinical outcomes of contemporary prostheses in patients with severe aortic stenosis and small annuli treated with TAVI.

Editorial, see page 196

Methods

STUDY DESIGN AND DEFINITION

The observational, retrospective TAVI-SMALL 2 registry included a total of 1,378 patients with severe native aortic valve stenosis and small aortic annuli (defined as an annular area <400 mm^2 and/or annular perimeter <72 mm on computed tomography) treated with transfemoral implantation of current-generation SEV (Evolut R and Evolut PRO [Medtronic]; ACURATE *neo* [Boston Scientific]; Portico [Abbott Vascular]) and BEV (SAPIEN 3 [Edwards Lifesciences]) at 16 high-volume centres **(Supplementary Figure 1)** between June 2011 and April 2020. This study complied with the Declaration of Helsinki and was approved by local ethics committees. All patients provided written informed consent for the procedure and subsequent data collection, based on local practice and/or local institutional review board approval.

Inclusion criteria were implantation via the transfemoral route of current-generation transcatheter heart valves in native aortic stenosis (both tricuspid and non-tricuspid anatomies) in patients with small aortic annuli. Exclusion criteria were valve-in-valve procedures, TAVI for pure aortic regurgitation and lack of preprocedural computed tomographic data.

Local multidisciplinary Heart Teams evaluated all patients and confirmed the indications for TAVI. All patients underwent preprocedural screening by means of clinical assessment (patient demographic features, New York Heart Association [NYHA] Functional Class, history of angina and/or syncope, comorbidities, laboratory examinations, surgical risk, and frailty evaluation), echocardiography and computed tomography. Aortic annular, leaflet, and left ventricular outflow tract calcifications were classified and graded using a semiquantitative scoring system, as previously described[11]. Also, computed tomography-derived annular eccentricity (maximum/minimum annular diameter) and percentage of oversizing according to the perimeter ([SEV perimeter/annulus perimeter–1]/100) and area ([BEV area/annulus area–1]/100) were calculated. Prosthesis type and size selection, as well as implantation technique and subsequent antithrombotic therapy, were left to the discretion of the treating physician at each centre.

The rationale of the study was to evaluate the impact of different prosthesis designs on transvalvular haemodynamics and clinical outcomes. Analyses were thus performed according to the mechanism of valve implantation, i.e., SEV (n=1,092: in particular Evolut R/Pro, n=750; ACURATE *neo*, n=170; and Portico, n=172) versus BEV (SAPIEN 3, n=286), and according to leaflet position, i.e., supra-annular valve (SAV; including Evolut R/Pro and ACURATE *neo*, n=920) versus intra-annular valve (IAV; including SAPIEN 3 and Portico, n=458). Additional analyses per implanted prosthesis were also performed.

ENDPOINTS

Primary endpoints were the predischarge mean aortic gradient and incidence of severe PPM. PPM was defined as an indexed effective orifice area (EOA) <0.85 cm^2/m^2 in patients with a body mass index (BMI) <30 kg/m^2; those with PPM were further divided into moderate (indexed EOA 0.65-0.85 cm^2/m^2) or severe PPM (indexed EOA <0.65 cm^2/m^2) groups. Indexed EOA <0.70 cm^2/m^2 and <0.55 cm^2/m^2 were the adjusted thresholds used for moderate and severe PPM, respectively, in patients with a BMI ≥30 kg/m^2, as per Valve Academic Research Consortium 3 endpoint definitions[12]. Additional analyses of PPM without BMI adjustment were also conducted. The EOA was calculated at predischarge transthoracic echocardiography with the continuity equation method; stroke volume was estimated via the left ventricular outflow tract (LVOT) diameter (outer-to-outer border of the valve stent) and velocity-time integral measured just underneath the ventricular margin of the valve stent[12]. The secondary endpoint was the incidence of predischarge more than mild paravalvular leak (PVL).

STATISTICAL ANALYSIS

Continuous variables are reported as mean±standard deviation or median±interquartile range, and were compared using the Student's t-test or the Mann-Whitney U test (or Wilcoxon rank-sum test) in case of 2-group comparisons on the basis of normality of data distribution and verified using the Shapiro-Wilk test. In case of continuous variable comparisons between more than 2 groups, analysis of variance was performed; Bartlett's test for equal variances was performed to assess if the variances were comparable between groups, and the Bonferroni correction was applied to adjust for multiple comparisons. Categorical variables are reported as percentage (number) and were compared using the chi-square test, without Yates' correction for continuity, or Fisher's exact test, as appropriate. Unadjusted survival curves for all-cause mortality were constructed with the use of Kaplan-Meier estimates and compared with the log-rank test. To account for selection bias between SAV- and IAV-treated patients and between SEV- and BEV-treated patients, a propensity score methodology with inverse probability of treatment weighting (IPTW) was performed[13,14]. Propensity scores predicting each patient's probability of undergoing TAVI with SAV or IAV and TAVI with SEV or BEV, respectively, were estimated with multivariable logistic regression including variables with a difference in their distribution between the treatment groups or deemed to be clinically relevant. The following covariates were included in the models used to estimate the propensity scores: age, BMI, sex, hypertension, chronic obstructive pulmonary disease (COPD), cerebrovascular disease, coronary artery disease, previous pacemaker (PM) or implantable cardioverter defibrillator (ICD) implant, NYHA Class III or IV, Society of Thoracic Surgeons Predicted Risk of Mortality (STS-PROM), preprocedural mean aortic valve (AV) gradient, ejection fraction and AV annular perimeter. Stabilised weights were computed from propensity scores by means of IPTW. The weight for SAV treatment was the inverse of the respective propensity score, whereas the weight for IAV treatment was the inverse of 1−propensity score. The weights for SEV and BEV treatment were calculated in the same way, starting from the respective propensity score. Post-IPTW adjustment, the balance of covariates between the treatment groups was assessed by means of standardised mean differences (SMD), and variables were considered balanced if the SMD was ≤10%[13]. Logistic regression models evaluating the impact of SAV versus IAV and of SEV versus BEV on severe PPM, severe PPM (non-BMI-adjusted) and more than mild PVL were weighted by IPTW, and IPTW-adjusted odds ratios (OR) with 95% confidence intervals (CI) were reported. Cox regression models evaluating the impact of SAV versus IAV and of SEV versus BEV on all-cause mortality were weighted using IPTW. The proportionality assumption was verified using the Schoenfeld residuals method. Adjusted Kaplan-Meier survival curves were generated by weighting the survival function with the IPTW in the 2 comparisons. Doubly robust IPTW adjustment was also performed, augmenting the logistic regression models with covariates that either were unbalanced after the initial IPTW adjustment (SMD >10%) or were considered clinically relevant for the outcome of interest (severe PPM)[15]. Considering the relatively low number of events, the variables of interest were added separately to the IPTW-adjusted models in order to avoid overfitting.

Clinical follow-up was censored at the date of death or latest available follow-up. Data for patients lost to follow-up were censored at the time of the last contact. A two-sided p-value <0.05 was considered statistically significant. Statistical analyses were performed using Stata version 16.0 (StataCorp).

Results

STUDY POPULATION AND CLINICAL FEATURES

Baseline characteristics of patients stratified according to both the mechanism of valve expansion and leaflet position are reported in **Table 1**. Treated patients were mostly female (89%), had a mean age of 83±6 years and were at moderate surgical risk (STS-PROM 5.7±4.0%). Weight and body surface area (BSA) were higher in patients with IAV and BEV versus SAV and SEV, respectively (p<0.001), as was BMI. Small, although statistically significant, differences were noted among groups with regard to clinical variables, such as hypertension, cerebrovascular disease, coronary artery disease, NYHA Functional Class at baseline, previous percutaneous coronary intervention, COPD, angina, atrial fibrillation and previous PM or ICD implantation. **Supplementary Table 1** includes baseline characteristics of the cohorts stratified according to the single prosthesis implanted.

ECHOCARDIOGRAPHIC AND COMPUTED TOMOGRAPHY FEATURES

Baseline echocardiographic and computed tomography features are shown in **Table 2**. Slightly higher preprocedural mean and peak aortic gradients and lower measured EOA were present in SAV versus IAV and SEV versus BEV cohorts, respectively, (p<0.001). The SAV and SEV groups also had lower ejection fractions (58±11% vs 61±10% and 58±11% vs 62±10%; both p<0.001) and a higher prevalence of baseline moderate or more aortic regurgitation, mitral regurgitation or tricuspid regurgitation when compared with IAV and BEV, respectively, while bicuspid valves were less common in the two former cohorts (3.4% vs 5.8%; p=0.053 and 3.5% vs 7.3%; p=0.007). Computed tomography-derived mean diameters and the area- and perimeter-derived diameters slightly differed between groups, with a trend to wider eccentricity in the IAV and BEV groups. Severe annular and LVOT calcifications were more frequent among patients with SAV and SEV, while severe leaflet calcifications differed only when comparing SEV and BEV. On the other hand, porcelain aorta was more common in IAV versus SAV and BEV versus SEV, respectively. Baseline echocardiographic and computed tomography features of single prosthesis cohorts are reported in **Supplementary Table 2**.

PROCEDURAL FEATURES

Procedural data are shown in **Table 3**. With respect to prosthesis selection, a higher proportion of THV with a nominal diameter of 25 mm or less were implanted among the IAV and BEV groups (30.8% vs 95.2% [SAV vs IAV] and 39.9% vs 98.9% [SEV vs

Table 1. Baseline demographic characteristics according to leaflet position and mechanism of valve expansion.

Characteristic	Overall (n=1,378)	Supra-annular valve (n=920)	Intra-annular valve (n=458)	*p*-value (supra-annular vs intra-annular)	Self-expanding valve (n=1,092)	Balloon-expandable valve (n=286)	*p*-value (self-expanding vs balloon-expandable)
Age, years	82.9±6.2	83.0±6.2	82.6±6.2	0.239	83.0±6.2	82.5±6.5	0.291
Female	89.5 (1,233)	89.3 (822)	89.7 (411)	0.824	89.6 (979)	88.8 (254)	0.680
Weight, kg	64.7±14.7	63.5±14.2	67.0±15.5	**<0.001**	63.9±14.2	67.5±16.4	**<0.001**
Height, cm	157.7±7.7	157.3±7.7	158.5±7.7	**0.006**	157.4±7.4	159.1±8.5	**0.001**
Body surface area, m^2	1.65±0.19	1.63±0.19	1.68±0.19	**<0.001**	1.64±0.18	1.69±0.21	**<0.001**
Body mass index, kg/m^2	25.9±5.4	25.6±5.3	26.6±5.6	**<0.001**	25.7±5.3	26.6±5.8	**0.018**
Hypertension	85.5 (1,177)	84.1 (773)	88.2 (404)	**0.042**	84.5 (922)	89.2 (255)	**0.047**
Diabetes mellitus	26.4 (364)	25.4 (234)	28.4 (130)	0.242	26.3 (287)	26.9 (77)	0.827
Dyslipidaemia	51.8 (712)	53.2 (488)	49.1 (224)	0.159	52.7 (574)	48.4 (138)	0.197
COPD	11.5 (158)	11.0 (101)	12.5 (57)	0.417	10.3 (112)	16.1 (46)	**0.006**
Peripheral artery disease or previous PTA	11.7 (156)	12.6 (113)	9.7 (43)	0.114	12.2 (130)	9.5 (26)	0.214
Cerebrovascular disease	10.4 (143)	8.7 (80)	13.8 (63)	**0.004**	9.3 (101)	14.7 (42)	**0.007**
Previous PCI	21.9 (301)	20.3 (186)	25.3 (115)	**0.035**	21.4 (233)	23.9 (68)	0.355
Previous CABG	6.0 (82)	5.6 (51)	6.8 (31)	0.365	5.6 (61)	7.3 (21)	0.268
Previous MI	9.5 (128)	9.1 (81)	10.3 (47)	0.464	9.3 (99)	10.2 (29)	0.656
Coronary artery disease	38.2 (525)	35.9 (329)	42.9 (196)	**0.012**	36.0 (391)	46.8 (134)	**0.001**
PM or ICD	11.4 (157)	10.4 (96)	13.3 (61)	0.112	10.6 (116)	14.3 (41)	**0.079**
Atrial fibrillation	29.4 (269)	31.3 (182)	26.2 (87)	0.106	31.6 (225)	21.9 (44)	**0.008**
Angina	20.2 (230)	19.2 (165)	23.4 (65)	0.134	19.0 (185)	27.8 (45)	**0.010**
NYHA Class III or IV	67.4 (929)	65.6 (604)	71.0 (325)	**0.048**	66.5 (726)	71.0 (203)	0.149
STS-PROM, %	5.7±4.0	5.9±4.3	5.5±3.3	**0.097**	5.7±4.1	5.7±3.6	0.951

Values are mean±standard deviation or % (n). The values in bold represent differences between groups with p<0.100. CABG: coronary artery bypass graft; COPD: chronic obstructive pulmonary disease; ICD: implantable cardioverter-defibrillator; MI: myocardial infarction; NYHA: New York Heart Association; PTA: percutaneous transluminal angioplasty; PCI: percutaneous coronary intervention; PM: pacemaker; STS-PROM: Society of Thoracic Surgeons Predicted Risk of Mortality

BEV]; p<0.001). When compared with IAV and BEV, SAV and SEV, respectively, had higher proportions of oversizing ≥15% (64.2% vs 34.3% and 61.0% vs 28.7%; p<0.001). The proportion of predilation was higher in IAV versus SAV (46.9% vs 39.5%; p<0.001) and SEV versus BEV (44.3% vs 32.9%; p<0.001). On the other hand, post-dilation was more common in the SAV (31.9% vs 19.6% in IAV; p<0.001) and SEV (32.9% vs 8.2% in BEV; p<0.001) groups. As shown in **Supplementary Table 3**, the ACURATE *neo* and Portico cohorts presented the highest rates of predilation (65.7% and 70.0%) and post-dilation (36.5% and 38.2%). No difference in the incidence of annular rupture was observed.

PROCEDURAL AND CLINICAL OUTCOMES

Clinical and procedural outcomes are reported in **Table 4**. The mean aortic valve gradients were higher in the IAV and BEV cohorts (7.8 vs 12.0 mmHg [SAV vs IAV] and 8.0 vs 13.6 mmHg [SEV vs BEV]; p<0.001). This was accompanied by a higher incidence of severe PPM with IAV and BEV (3.6% vs 8.8%; p=0.007 and 4.6% vs 8.7%; p=0.041) **(Central illustration)**, in turn paralleled by a higher proportion of severe PPM with no BMI adjustment, moderate PPM and any degree of PPM (p<0.001). The SMDs before and after covariate balancing with the IPTW method are illustrated in **Figure 1** and **Supplementary Table 4**. After IPTW adjustment, SAV implantation remained a stronger protective factor for the development of severe PPM than SEV implantation (p=0.002 and p=0.029, respectively). On the other hand, SAV alone protected from severe PPM (non-BMI-adjusted) **(Table 5)**, and doubly robust analyses were more consistent with SAV than with SEV **(Supplementary Table 5)**. Among single THV patients, those with Portico and SAPIEN 3 had the highest mean aortic valve gradients (9.2±4.5 and 13.6±4.7 mmHg; overall p<0.001) and incidence of severe PPM (9.0% and 8.7%; overall p=0.058) **(Supplementary Table 6, Supplementary Figure 2)**.

Acute complications were rare, with no differences between groups with regard to vascular complications or major bleeding events. More than mild PVL was more common after SEV versus BEV implantation (11.6% vs 2.6%; p<0.001) **(Central illustration)**, while more than moderate PVL was more common after SAV versus IAV (p=0.043) and SEV versus BEV (p=0.052). SEV, but not SAV, implantation increased the risk of more than mild PVL after IPTW adjustment **(Table 5)**. Of note, the highest incidence of more than mild PVL was observed with Portico (19.0% vs 9.9% Evolut R/Pro, 11.2% ACURATE *neo* and 2.6% SAPIEN 3; p<0.001). When compared with BEV, SEV recipients had a higher incidence of permanent pacemaker implantation (PPI) and second valve implantation (13.5% vs 8.1%; p=0.013 and 2.0% vs 0.3%; p=0.065, respectively). When comparing single prostheses, patients with the SAPIEN 3 had the lowest incidence of PPI (8.1%; p=0.039) **(Supplementary Table 6)**.

Table 2. Baseline echocardiographic and computed tomography characteristics according to leaflet position and mechanism of valve expansion.

Characteristic	Overall (n=1,378)	Supra-annular valve (n=920)	Intra-annular valve (n=458)	*p*-value (supra-annular vs intra-annular)	Self-expanding valve (n=1,092)	Balloon-expandable valve (n=286)	*p*-value (self-expanding vs balloon-expandable)
Mean AV gradient, mmHg	47.7±16.0	49.0±16.1	45.3±15.5	**<0.001**	48.6±16.1	44.3±15.3	**<0.001**
Maximum AV gradient, mmHg	77.6±24.8	80.0±24.7	72.9±24.2	**<0.001**	79.0±24.7	72.3±24.4	**<0.001**
EOA, cm^2	0.64±0.21	0.63±0.18	0.66±0.25	**0.023**	0.64±0.19	0.67±0.27	**0.034**
sPAP, mmHg	40.3±13.7	39.6±13.0	41.9±15.1	**0.012**	40.1±13.3	41.5±15.2	0.189
TAPSE, mm	20.9±3.6	21.0±3.7	20.3±2.9	**0.076**	21.0±3.6	20.0±2.9	**0.059**
Bicuspid AV	4.3 (49)	3.4 (24)	5.8 (25)	**0.053**	3.5 (30)	7.3 (19)	**0.007**
Moderate or greater AR	6.7 (83)	8.3 (67)	3.8 (16)	**0.003**	7.6 (74)	3.4 (9)	**0.017**
Moderate or greater MR	8.8 (112)	10.4 (88)	5.6 (24)	**0.004**	10.4 (105)	2.6 (7)	**<0.001**
Moderate or greater TR	6.9 (74)	8.1 (54)	5.0 (20)	**0.056**	7.8 (65)	3.8 (9)	**0.033**
Ejection fraction, %	59.2±10.7	58.1±10.9	61.4±9.9	**<0.001**	58.4±10.6	62.2±10.2	**<0.001**
LVEF <40%	5.1 (71)	6.1 (56)	3.3 (15)	**0.026**	5.7 (62)	3.1 (9)	**0.085**
CT data							
Mean annular diameter, mm	21.2±1.3	21.2±1.4	21.3±1.1	**0.084**	21.2±1.3	21.4±1.0	**0.005**
Maximum diameter, mm	23.7±1.8	23.6±1.9	23.9±1.6	**<0.001**	23.6±1.9	24.0±1.4	**0.005**
Minimum diameter, mm	18.8±1.8	18.8±1.9	18.7±1.6	0.457	18.7±1.9	18.9±1.5	0.212
Annular eccentricity	1.27±0.17	1.27±0.17	1.29±0.17	**0.029**	1.27±0.17	1.28±0.18	0.553
Mean aortic annular perimeter, mm	66.9±4.3	67.3±3.6	66.0±5.3	**<0.001**	67.4±3.6	65.0±5.9	**<0.001**
Mean aortic annular area, mm^2	350.1±34.4	347.1±35.5	355.5±31.6	**<0.001**	346.5±35.1	362.3±28.7	**<0.001**
Area-derived diameter, mm	21.1±1.1	21.0±1.1	21.3±1.0	**<0.001**	21.0±1.1	21.5±0.9	**<0.001**
Perimeter-derived diameter, mm	21.3±1.5	21.4±1.2	21.0±1.7	**<0.001**	21.5±1.1	20.7±1.9	**<0.001**
Severe leaflet calcification	19.3 (185)	18.5 (107)	20.6 (78)	0.421	17.1 (115)	24.5 (70)	**0.008**
Severe annular calcification	4.4 (38)	6.2 (29)	2.2 (9)	**0.005**	5.6 (34)	1.5 (4)	**0.008**
Severe LVOT calcification	4.1 (40)	5.7 (34)	1.6 (6)	**0.001**	5.2 (36)	1.4 (4)	**0.006**
LMCA diameter, mm	12.5±2.6	12.4±2.5	12.6±2.7	0.184	12.3±2.5	12.8±2.6	**0.003**
RCA diameter, mm	14.4±2.8	14.2±3.0	14.6±2.5	**0.034**	14.3±2.9	14.7±2.5	**0.042**
Sinotubular junction diameter, mm	25.9±2.7	25.8±2.8	26.0±2.5	0.144	25.9±2.8	25.9±2.4	0.927
Sinus of Valsalva diameter, mm	28.7±2.5	28.8±2.5	28.6±2.5	0.180	28.9±2.5	28.4±2.5	**0.013**
Ascending aorta diameter, mm	31.9±3.9	31.6±3.9	32.3±3.9	**0.016**	31.9±4.0	32.0±3.8	0.657
Porcelain aorta	5.1 (61)	2.7 (21)	9.4 (40)	**<0.001**	3.2 (30)	11.9 (31)	**<0.001**

Values are mean±standard deviation or % (n). The values in bold represent differences between groups with p<0.100. AR: aortic regurgitation; AV: aortic valve; CT: computed tomography; EOA: effective orifice area; LMCA: left main coronary artery; LVEF: left ventricular ejection fraction; LVOT: left ventricular outflow tract; MR: mitral regurgitation; RCA: right coronary artery; RV: right ventricular; sPAP: systolic pulmonary artery pressure; TAPSE: tricuspid annular plane systolic excursion; TR: tricuspid regurgitation

At a median follow-up of 377 days (interquartile range 168-700 days), no differences were observed between patients in the SAV versus IAV and SEV versus BEV cohorts in terms of all-cause mortality (9.4% vs 11.9%; p=0.172 and 9.8% vs 12.3%; p=0.218). When compared with SAV at Kaplan-Meier analysis, the use of IAV did not result in an increased risk of all-cause mortality (p=0.748). Similarly, no difference in all-cause mortality was observed between SEV and BEV (p=0.687) at the time-to-event analysis. Results were confirmed when comparing single-prosthesis cohorts (p=0.667) **(Supplementary Figure 3)**. No significant differences in all-cause mortality were present when comparing SAV versus IAV and SEV versus BEV at Cox regression analysis, neither before nor after IPTW adjustment **(Table 5, Figure 2)**. A trend towards decreased cardiovascular mortality was observed when comparing SAV and IAV (2.8% vs 4.5%; p=0.099), with the only significant difference at analysis per single prosthesis present when comparing Evolut R/Pro with Portico (2.7% vs 5.4%; p=0.021) **(Supplementary Table 6)**.

The incidence of myocardial infarction, stroke or transient ischaemic attack and hospitalisation for heart failure did not differ between groups. Acute kidney injury was more common after ACURATE *neo* and Portico implantations (p=0.020) **(Supplementary Table 6)** in the analysis per single prosthesis.

Discussion

The objective of the present study was to compare the forward flow haemodynamics and clinical outcomes of the currently available THV in patients with severe aortic stenosis and small annuli. The main findings are the following:

- IAV and BEV are associated with increased mean aortic valve (AV) gradients and the incidence of severe PPM when compared to SAV and SEV, respectively;

Table 3. Procedural characteristics according to leaflet position and mechanism of valve expansion.

Characteristic	Overall (n=1,378)	Supra-annular valve (n=920)	Intra-annular valve (n=458)	*p*-value (supra-annular vs intra-annular)	Self-expanding valve (n=1,092)	Balloon-expandable valve (n=286)	*p*-value (self-expanding vs balloon-expandable)
Valve size 25 mm or less	52.2 (719)	30.8 (283)	95.2 (436)	**<0.001**	39.9 (436)	98.9 (283)	**<0.001**
Oversizing by perimeter	15.0±8.7	17.5±7.2	11.2±9.9	**<0.001**	17.0±7.1	9.5±11.4	**<0.001**
Oversizing by perimeter ≥15%	54.1 (745)	64.2 (591)	33.6 (154)	**<0.001**	61.0 (666)	27.6 (69)	**<0.001**
Oversizing by area	36.9±21.2	45.5±18.4	22.0±17.3	**<0.001**	44.4±17.7	11.9±10.8	**<0.001**
Oversizing by area ≥15%	82.6 (1,138)	96.3 (886)	55.0 (252)	**<0.001**	96.7 (1,056)	28.7 (82)	**<0.001**
Oversizing ≥15%	54.3 (748)	64.2 (591)	34.3 (157)	**<0.001**	61.0 (666)	28.7 (82)	**<0.001**
Predilation	41.9 (573)	39.5 (361)	46.9 (212)	**0.009**	44.3 (481)	32.9 (92)	**0.001**
Post-dilation	27.8 (380)	31.9 (292)	19.6 (88)	**<0.001**	32.9 (357)	8.2 (23)	**<0.001**
Annular rupture	0.3 (4)	0.2 (2)	0.4 (2)	0.548	0.3 (3)	0.3 (1)	0.909

Values are mean±standard deviation or % (n). The values in bold represent differences between groups with p<0.100. Oversizing ≥15% refers to oversizing by perimeter ≥15% for self-expanding valves and oversizing by area ≥15% for balloon-expandable valves.



Figure 1. *Standardised mean differences (SMDs) of the covariates used for propensity score modelling before and after inverse probability of treatment weighting (IPTW) adjustment for comparisons of SAV versus IAV (A) and SEV versus BEV (B). After adjustment, all covariates showed SMDs within the 10% cut-off (dashed vertical lines), except AV annular perimeter in the SEV versus BEV comparison (−11.2%). AV: aortic valve; BEV: balloon-expandable valve; BMI: body mass index; CAD: coronary artery disease; COPD: chronic obstructive pulmonary disease; IAV: intra-annular valve; ICD: implantable cardioverter-defibrillator; LVEF: left ventricular ejection fraction; NYHA: New York Heart Association; PM: pacemaker; SAV: supra-annular valve; SEV: self-expanding valve; STS-PROM: Society of Thoracic Surgery Predicted Risk of Mortality*

- The incidence of more than mild PVL was higher after SEV versus BEV, but not SAV versus IAV implantation;
- IPTW-adjusted logistic regression analyses confirmed SAV as a protective factor from severe PPM, regardless of its definition, and BEV as protective factor from more than mild PVL.

Of patients treated with SAVR, up to one-half and one-quarter have PPM and severe PPM, respectively[2]. A recent meta-analysis conducted on 745 patients described a relative risk reduction of 77% in the incidence of PPM in patients treated with TAVI as compared to surgery[9]. Nonetheless, not all THV are born equal. Indeed, not only did comparison of SAVR and TAVI with a SAPIEN 3 intra-annular BEV in the PARTNER 3 Trial show similar transvalvular gradients and incidence of severe PPM (4.6 vs 6.3%, respectively; p=0.30)[16], but also SAPIEN 3 implantation was identified as an independent predictor of PPM in the OCEAN-TAVI registry[17]. Notwithstanding the slight, although significant, difference in BSA between groups, the lower mean AV gradients and incidence of severe PPM with SAV versus IAV implantation further clarify the role of leaflet position in the development of PPM in patients with small annuli, in line with previous evidence from the TAVI-SMALL registry, which showed an increased risk of PPM in SEV with intra-annular leaflets[8,10]. Similarly, in a recent subanalysis of propensity score-matched patients from the OCEAN-TAVI registry treated with a third-generation THV, Evolut R outperformed SAPIEN 3 in terms of the mean AV gradient[18]. Schofer et al reported data from 1,309 patients undergoing TAVI with different THV: the lowest rate of severe PPM was present with supra-annular SEV (4%), whereas the highest rate was detected in patients with self-expanding cusp-fixated prostheses (25%) and intra-annular BEV (24%)[19]. The importance of leaflet position in THV implanted in patients with small annuli has been recently reported in a retrospective registry of 1,069 patients, where a higher incidence of PPM was found after the implantation of intra-annular BEV or intra-annular mechanically expandable THV compared to intra- and supra-annular SEV; SEV implantation itself was linked to a lower incidence of PPM[20]. The haemodynamic advantage of TAVI with supra-annular valves

Table 4. Post-procedural characteristics and follow-up according to leaflet position and mechanism of valve expansion.

Characteristic	Overall (n=1,378)	Supra-annular valve (n=920)	Intra-annular valve (n=458)	*p*-value (supra-annular vs intra-annular)	Self-expanding valve (n=1,092)	Balloon-expandable valve (n=286)	*p*-value (self-expanding vs balloon-expandable)
Predischarge							
Any vascular complication	14.0 (192)	13.6 (124)	14.8 (68)	0.545	14.2 (154)	13.3 (38)	0.678
Major vascular complication	4.7 (65)	4.4 (40)	5.5 (25)	0.386	4.5 (49)	5.6 (16)	0.453
Need for second valve implantation	1.7 (23)	1.7 (16)	1.5 (7)	0.770	2.0 (22)	0.3 (1)	**0.065**
Mean AV gradient, mmHg	9.3±4.8	7.8±3.9	12.0±5.1	**<0.001**	8.0±4.1	13.6±4.7	**<0.001**
Maximum AV gradient, mmHg	16.5±8.2	14.5±6.8	22.4±8.9	**<0.001**	14.8±7.1	24.8±7.7	**<0.001**
EOA, cm^2	1.61±0.45	1.74±0.50	1.47±0.34	**<0.001**	1.72±0.49	1.41±0.29	**<0.001**
Indexed EOA, cm^2/m^2	1.00±0.30	1.11±0.31	0.88±0.23	**<0.001**	1.08±0.31	0.84±0.19	**<0.001**
Any PPM (non-BMI-adjusted)	33.6 (211)	16.9 (56)	52.4 (155)	**<0.001**	20.5 (84)	58.3 (127)	**<0.001**
Any PPM	28.0 (176)	13.5 (45)	44.3 (131)	**<0.001**	16.6 (68)	49.5 (108)	**<0.001**
Moderate PPM (non-BMI-adjusted)	25.0 (157)	12.6 (42)	38.8 (115)	**<0.001**	14.9 (61)	44.0 (96)	**<0.001**
Moderate PPM	22.0 (138)	9.9 (33)	35.5 (105)	**<0.001**	11.9 (49)	40.8 (89)	**<0.001**
Severe PPM (non-BMI-adjusted)	8.6 (54)	4.2 (14)	13.5 (40)	**<0.001**	5.6 (23)	14.2 (31)	**<0.001**
Severe PPM	6.0 (38)	3.6 (12)	8.8 (26)	**0.007**	4.6 (19)	8.7 (19)	**0.041**
More than mild PVL	9.4 (107)	10.1 (73)	8.3 (34)	0.315	11.6 (100)	2.6 (7)	**<0.001**
More than moderate PVL	1.1 (12)	1.5 (11)	0.2 (1)	**0.043**	1.4 (12)	0	**0.052**
PPI	12.4 (169)	13.2 (120)	10.7 (49)	0.187	13.5 (146)	8.1 (23)	**0.013**
BARC major bleeding	5.9 (81)	6.4 (59)	4.8 (22)	0.231	5.9 (64)	5.9 (17)	0.958
Follow-up							
All-cause mortality	10.3 (129)	9.4 (76)	11.9 (53)	0.172	9.8 (95)	12.3 (34)	0.218
Cardiovascular mortality	3.4 (42)	2.8 (22)	4.5 (20)	**0.099**	3.2 (31)	4.0 (11)	0.537
Myocardial infarction	1.1 (12)	1.0 (7)	1.3 (5)	0.763	1.2 (10)	0.7 (2)	0.741
TIA/stroke	3.3 (36)	3.9 (28)	2.3 (8)	0.182	3.6 (29)	2.6 (7)	0.404
Acute kidney injury	2.9 (27)	3.2 (19)	2.4 (8)	0.497	3.4 (22)	1.9 (5)	0.284
Hospitalisation for HF	6.2 (65)	5.9 (42)	6.8 (23)	0.598	6.1 (48)	6.6 (17)	0.770

Values are mean±standard deviation or % (n). The values in bold represent differences between groups with p<0.100. AV: aortic valve; BARC: Bleeding Academic Research Consortium; BMI: body mass index; EOA: effective orifice area; HF: heart failure; PPI: permanent pacemaker implantation; PPM: prosthesis-patient mismatch; PVL: paravalvular leak; TIA: transient ischaemic attack

in patients with small annuli has been addressed in other studies. Indeed, in the CHOICE-Extend registry, the supra-annular SEV (Evolut R) also had higher indexed EOA and lower post-procedural mean gradients and PPM than the intra-annular BEV (SAPIEN 3)[7]. Another supra-annular SEV, the ACURATE *neo*, was comparable to the Evolut R, in terms of the incidence of severe PPM, in a recent randomised trial[21], which similarly resulted in lower gradients and lower rate of severe PPM when compared with the SAPIEN 3 among 246 propensity score-matched patients with small aortic annuli[22]. These findings were also confirmed in Japanese patients with very small annuli[23]. In addition, both oversizing and post-dilation, previously shown to protect from the incidence of PPM[10], were more common in SAV and SEV versus IAV and BEV, respectively. Of note, the method used for measuring PPM appears to be important. Indeed, not only did reclassification of PPM using a predicted EOA reveal a lower incidence with respect to a measured EOA-based method in a large cohort treated mainly with BEV, but also a stronger association with high residual gradient was appreciated with predicted versus measured PPM. Further studies will need to be undertaken to adequately address the definition of PPM[24].

The lower incidence of more than mild PVL after BEV implantation parallels available randomised evidence[25,26] and supports the relevance of an external skirt or seal at the inflow portion of the THV, also in patients with small annuli. We expect new prosthesis iterations, namely Navitor (Abbott) (Sondergaard L. 30-day outcomes from a next generation TAVI device with an active sealing cuff. EuroPCR 2021. Paris, France) and the ACURATE *neo*2 (Boston Scientific),[27] to mitigate the rates of PVL. Of note, the observed increased risk of acute kidney injury with the Portico and ACURATE *neo* might also be related to the increased use of contrast agent and the performance of predilation and post-dilation, undertaken in order to mitigate the rates of PVL[28].

The increased risk of PPI after SEV versus BEV is similar to results from direct randomised comparisons in the SOLVE-TAVI, CHOICE and PORTICO-IDE trials[25,26]. Also, the significant difference in the incidence of PPI after implantation of SAPIEN 3 versus Evolut R/Pro or Portico, but not ACURATE *neo*, confirms the favourable profile of the latter prosthesis among SEV in terms of impact on persistent conduction disturbances after TAVI[21,29].

The absence of significant differences in all-cause mortality between groups, confirmed at IPTW-adjusted analyses, needs to be acknowledged in light of the non-uniform distribution of patients among groups and the related lack of power in assessing this outcome. These results parallel those from the TAVI-SMALL registry[8] and those recently reported in a multicentre analysis of patients with

Table 5. Unadjusted and adjusted risk of clinical outcomes.

Characteristic	Overall (n=1,378)	Supra-annular valve (n=920)	Intra-annular valve (n=458)	Unadjusted OR/HR (95% CI)*	*p*-value	IPTW-adjusted HR/ OR (95% CI)†	*p*-value
Severe PPM	6.0 (38)	3.6 (12)	8.8 (26)	0.22 (0.11-0.44)	**<0.001**	0.25 (0.10-0.60)	**0.002**
Severe PPM (non-BMI-adjusted)	8.6 (54)	4.2 (14)	13.5 (40)	0.28 (0.15-0.53)	**<0.001**	0.36 (0.16-0.82)	**0.015**
More than mild PVL	9.4 (107)	10.1 (73)	8.3 (34)	1.24 (0.81-1.90)	0.319	0.98 (0.60-1.60)	0.944
All-cause mortality	10.3 (129)	9.4 (76)	11.9 (53)	1.10 (0.77-1.56)^	0.604	1.34 (0.81-2.23)^	0.255
Characteristic	**Overall (n=1,378)**	**Self-expanding valve (n=1,092)**	**Balloon-expandable valve (n=286)**	**Unadjusted OR/HR (95% CI)***	***p*-value**	**IPTW-adjusted HR/ OR (95% CI)†**	***p*-value**
Severe PPM	6.0 (38)	4.6 (19)	8.6 (19)	0.25 (0.13-0.48)	**<0.001**	0.40 (0.18-0.91)	**0.029**
Severe PPM (non-BMI-adjusted)	8.6 (54)	5.6 (23)	14.2 (31)	0.36 (0.20-0.63)	**<0.001**	0.66 (0.33-1.33)	0.246
More than mild PVL	9.4 (107)	11.6 (100)	2.6 (7)	4.87 (2.24-10.6)	**<0.001**	4.85 (1.70-13.9)	**0.003**
All-cause mortality	10.3 (129)	9.8 (95)	12.3 (34)	1.26 (0.85-1.87)^	0.258	1.59 (0.90-2.81)^	0.109

Results reported as % (number of events), HR, OR, and 95% CI. Comparisons are SAV versus IAV and SEV versus BEV. *Generated with univariable logistic/Cox regression analysis. †Generated with logistic/Cox regression modelling after IPTW adjustment. ^HR was analysed via Cox regression analysis for the outcome all-cause mortality (at a median follow-up of 377 days). All other outcomes had OR assessed via logistic regression analysis. The values in bold represent differences between groups with p<0.100. AV: aortic valve; BEV: balloon-expandable valve; BMI: body mass index; CI: confidence interval; HR: hazard ratio; IAV: intra-annular valve; IPTW: inverse probability of treatment weighting; OR: odds ratio; PPM: prosthesis-patient mismatch; PVL: paravalvular leak; SAV: supra-annular valve; SEV: self-expanding valve

EuroIntervention

CENTRAL ILLUSTRATION Incidence of PPM and more than mild PVL according to leaflet position and mechanism of valve expansion.



BEV: balloon-expandable valve; IAV: intra-annular valve; PPM: prosthesis-patient mismatch; PVL: paravalvular leak; SAV: supra-annular valve; SEV: self-expandable valve

small annuli, where 30-day and 12-month mortality rates were similar between patients treated with the SAPIEN 3, Evolut, ACURATE *neo*, Portico and Lotus THV[20]. Of note, numerical differences favouring SAV versus IAV and SEV versus BEV were present, as were differences in cardiovascular mortality when comparing SAV and IAV (2.8% vs 4.5%; p=0.099) and Evolut R/Pro with Portico (2.7% vs 5.4%; p=0.021), although the observational, retrospective nature of the current study represents an additional relevant limitation. Previous 30-day results from head-to-head randomised comparisons of SAV and IAV revealed either no difference in the valve-related efficacy endpoint between groups[25] or a higher incidence of the safety and efficacy endpoint in SAV versus IAV[29]. The possibility that the favourable forward haemodynamic profile linked to SAV implantation might be of prognostic significance in patients with small annuli will need to be further addressed at long-term follow-up analysis and in randomised studies. In this setting, results



Figure 2. *Non-adjusted and IPTW-adjusted Kaplan-Meier curves of all-cause mortality in patients treated with SAV versus IAV and SEV versus BEV. At a median follow-up of 377 (interquartile range 168-700) days, no significant difference in the risk of all-cause mortality was evident in either the non-adjusted comparison of SAV versus IAV (A) and SEV versus BEV (B) the adjusted comparison of SAV versus IAV (C) and SEV versus BEV (D). The number of patients at risk during follow-up is not applicable in the adjusted inverse probability of treatment weight analysis. BEV: balloon-expandable valve; CI: confidence interval; HR: hazard ratio; IAV: intra-annular valve; IPTW: inverse probability of treatment weighting. SAV: supra-annular valve; SEV: self-expanding valve*

from the ongoing Small Annuli Randomized to Evolut or SAPIEN Trial (SMART) will be of paramount importance (ClinicalTrials.gov: NCT04722250). No differences between groups were observed at 12 months, in terms of transient ischaemic attack or stroke, myocardial infarction or hospitalisation for heart failure.

Limitations

First, selection and confounding bias cannot be excluded because of the observational nature of our study. Second, underreporting or missing echocardiographic and follow-up data need to be acknowledged. Third, the absence of core laboratory echocardiographic and computed tomography evaluation could have impacted the assessment of baseline and procedural results. Fourth, implantation depth was not assessed in the current study. Fifth, data on simultaneous haemodynamic measurements were not available. Also, the incidence of predicted PPM was not assessed in this study. Finally, we need to acknowledge the lack of power in assessing differences in all-cause mortality deriving from the non-uniform distribution of patients among groups, although it should be recognised that our retrospective cohort study provides a relevant real-world picture of the practice at 16 high-volume valve centres.

Conclusions

The TAVI-SMALL 2 multicentre observational retrospective registry, including patients with aortic stenosis and small aortic annuli undergoing transfemoral TAVI, suggests that the implantation of SAV and SEV yields lower mean aortic valve gradients and protects from the development of severe PPM when compared to IAV and BEV, respectively, at the expense of higher rates of PVL. Also, PPI was more common after SEV than BEV implantation. Randomised trials assessing the long-term prognostic relevance of the type of THV implanted in small aortic annuli are eagerly awaited.

Impact on daily practice

The TAVI-SMALL 2 international multicentre registry is the largest to date to compare the performance of contemporary transcatheter valves in patients with aortic stenosis and small annuli undergoing TAVI. SAV and SEV yielded lower mean aortic valve gradients and incidence of severe PPM when compared to IAV and BEV, respectively, at the expense of higher rates of paravalvular leak. Permanent pacemaker implantation was more common after SEV than BEV implantation. This study supports the implantation of SAV for superior forward flow haemodynamics in patients with small annuli. The long-term relevance of PPM after TAVI will need to be addressed in larger randomised studies.

Appendix. Authors' affiliations

1. Montefiore Medical Center, New York, NY, USA; 2. Department of Biomedical Sciences, Humanitas University,

Pieve Emanuele-Milan, Italy; 3. Cardio Center, IRCCS Humanitas Research Hospital, Rozzano-Milan, Italy; 4. Institute of Cardiology, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy; 5. Department of Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, the Netherlands; 6. U.O.C. Cardiologia, Centro Alte Specialità e Trapianti, A.O.U. Policlinico "G. Rodolico-San Marco", Catania, Italy; 7. Hospital de Santa Cruz, Centro Hospitalar de Lisboa Ocidental, Nova Medical School, CEDOC, Lisbon, Portugal; 8. HerzZentrum Hirslanden Zurich, Zurich, Switzerland and University of Zurich, Zurich, Switzerland; 9. DZHK (German Center for Cardiovascular Research), Partner Site RheinMain, Frankfurt am Main, Germany; 10. Department of Cardiology, IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy; 11. GVM Care & Research, Maria Cecilia Hospital, Ravenna, Italy; 12. Department of Cardiology, Tokai University Hospital, Kanagawa, Japan; 13. Cardiology Unit, Sant'Orsola Polyclinic, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; 14. Interventional Cardiology Unit, Cardiovascular Department, Fondazione Poliambulanza Istituto Ospedaliero, Brescia, Italy; 15. Clinical and Interventional Unit, Sant'Ambrogio Cardio-Thoracic Center, Milan, Italy; 16. Division of Cardiology, Department of Medicine, University of Verona, Verona, Italy; 17. Department of Cardiology, Kerckhoff Heart Center, Bad Nauheim, Germany; 18. Cardio-Thoracic-Vascular Department, IRCCS Ospedale San Raffaele, Milan, Italy.

Guest editor

This paper was guest edited by Franz-Josef Neumann, MD; *Department of Cardiology and Angiology II, University Heart Center Freiburg - Bad Krozingen, Bad Krozingen, Germany.*

Conflict of interest statement

M. Barbanti is a consultant for Medtronic, Boston Scientific, and Edwards Lifesciences. R. Teles has received a received a research grant (to the institution) from Abbott. M. Adamo discloses speaker fees from Abbott and Medtronic. M. Taramasso discloses consultant or consultancy fees from Abbott Vascular, Edwards Lifesciences, Boston Scientific, Medtronic, Shenqi Medical, VentriMend, Simulands, Occlufit, MTEx, MEDIRA, and HI-D Imaging; and serves on the advisory board of Abbott. G. Stefanini has received a research grant (to the institution) from Boston Scientific; and has received speaking and consulting fees from Abbott Vascular, Boston Scientific, and Pfizer/BMS. W-K. Kim is a proctor for Boston Scientific, Meril Life Sciences, and Abbott; and has received speaking fees from Boston Scientific, Abbott, Medtronic, Edwards Lifesciences, Meril Life, and Shockwave Medical. F. Maisano discloses grant and/or research institutional support from Abbott, Medtronic, Edwards Lifesciences, Biotronik, Boston Scientific, NVT, and Terumo; consulting fees, personal and institutional honoraria from Abbott, Medtronic, Edwards Lifesciences, Xeltis, Cardiovalve, Occlufit, Simulands, and Mtex; royalty income/IP rights from Edwards Lifesciences; a shareholder position (including share options) at Cardiogard, Cardiovalve, Magenta, SwissVortex, Transseptal Solutions, 4Tech, and Perifect. N.M. Van Mieghem has received institutional research grants from Abbott, Boston Scientific, Edwards Lifesciences, Medtronic, Abiomed, PulseCath BV, Daiichi Sankyo, and Biotronik. B. Reimers has received speaking honoraria from Boston Scientific. A. Latib serves on the advisory boards of Medtronic, Edwards Lifesciences, Boston Scientific, Philips, and Abbott. The other authors have no conflicts of interest to declare, relevant to the contents of this paper. The Guest Editor reports lecture fees paid to his institution from Amgen, Bayer Healthcare, Biotronik, Boehringer Ingelheim, Boston Scientific, Daiichi Sankyo, Edwards Lifesciences, Ferrer, Pfizer, and Novartis; consultancy fees paid to his institution from Boehringer Ingelheim; and grant support from Bayer Healthcare, Boston Scientific, Biotronik, Edwards Lifesciences, GlaxoSmithKline, Medtronic, and Pfizer.

References

1. Rahimtoola SH. The problem of valve prosthesis-patient mismatch. *Circulation.* 1978;58:20-4.

2. Dayan V, Vignolo G, Soca G, Paganini JJ, Brusich D, Pibarot P. Predictors and Outcomes of Prosthesis-Patient Mismatch After Aortic Valve Replacement. *JACC Cardiovasc Imaging.* 2016;9:924-33.

3. Bleiziffer S, Hettich I, Hutter A, Wagner A, Deutsch MA, Piazza N, Lange R. Incidence and impact of prosthesis-patient mismatch after transcatheter aortic valve implantation. *J Heart Valve Dis.* 2013;22:309-16.

4. Okuno T, Khan F, Asami M, Praz F, Heg D, Winkel MG, Lanz J, Huber A, Gräni C, Räber L, Stortecky S, Valgimigli M, Windecker S, Pilgrim T. Prosthesis-Patient Mismatch Following Transcatheter Aortic Valve Replacement With Supra-Annular and Intra-Annular Prostheses. *JACC Cardiovasc Interv.* 2019;12:2173-82.

5. Leone PP, Fazzari F, Cannata F, Sanz-Sanchez J, Mangieri A, Monti L, Cozzi O, Stefanini GG, Bragato R, Colombo A, Reimers B, Regazzoli D. Clinical and Technical Challenges of Prosthesis-Patient Mismatch After Transcatheter Aortic Valve Implantation. *Front Cardiovasc Med.* 2021;8:670457.

6. Rodés-Cabau J, Pibarot P, Suri RM, Kodali S, Thourani VH, Szeto WY, Svensson LG, Dumont E, Xu K, Hahn RT, Leon MB. Impact of aortic annulus size on valve hemodynamics and clinical outcomes after transcatheter and surgical aortic valve replacement: insights from the PARTNER Trial. *Circ Cardiovasc Interv.* 2014;7:701-11.

7. Abdelghani M, Mankerious N, Allali A, Landt M, Kaur J, Sulimov DS, Merten C, Sachse S, Mehilli J, Neumann FJ, Frerker C, Kurz T, El-Mawardy M, Richardt G, Abdel-Wahab M. Bioprosthetic Valve Performance After Transcatheter Aortic Valve Replacement With Self-Expanding Versus Balloon-Expandable Valves in Large Versus Small Aortic Valve Annuli: Insights From the CHOICE Trial and the CHOICE-Extend Registry. *JACC Cardiovasc Interv.* 2018;11:2507-18.

8. Regazzoli D, Chiarito M, Cannata F, Pagnesi M, Miura M, Ziviello F, Picci A, Reifart J, De Marco F, Bedogni F, Adamo M, Curello S, Teles R, Taramasso M, Barbanti M, Tamburino C, Stefanini GG, Mangieri A, Giannini F, Pagnotta PA, Maisano F, Kim WK, Van Mieghem NM, Colombo A, Reimers B, Latib A; TAVI-SMALL Investigators. Transcatheter Self-Expandable Valve Implantation for Aortic Stenosis in Small Aortic Annuli: The TAVI-SMALL Registry. *JACC Cardiovasc Interv.* 2020;13:196-206.

9. Takagi H, Umemoto T; ALICE (All-Literature Investigation of Cardiovascular Evidence) Group. Prosthesis-Patient Mismatch After Transcatheter Aortic Valve Implantation. *Ann Thorac Surg.* 2016;101:872-80.

10. Leone PP, Regazzoli D, Pagnesi M, Sanz-Sanchez J, Chiarito M, Cannata F, Van Mieghem NM, Barbanti M, Tamburino C, Teles R, Adamo M, Miura M, Maisano F, Kim WK, Bedogni F, Stefanini G, Mangieri A, Giannini F, Colombo A, Reimers B, Latib A; TAVI-SMALL Investigators. Predictors and Clinical Impact of Prosthesis-Patient Mismatch After Self-Expandable TAVR in Small Annuli. *JACC Cardiovasc Interv.* 2021;14:1218-28.

11. Barbanti M, Yang TH, Rodès Cabau J, Tamburino C, Wood DA, Jilaihawi H, Blanke P, Makkar RR, Latib A, Colombo A, Tarantini G, Raju R, Binder RK, Nguyen G, Freeman M, Ribeiro HB, Kapadia S, Min J, Feuchtner G, Gurtvich R,

Alqoofi F, Pelletier M, Ussia GP, Napodano M, de Brito FS Jr, Kodali S, Norgaard BL, Hansson NC, Pache G, Canovas SJ, Zhang H, Leon MB, Webb JG, Leipsic J. Anatomical and procedural features associated with aortic root rupture during balloon-expandable transcatheter aortic valve replacement. *Circulation.* 2013;128:244-53.

12. VARC-3 WRITING COMMITTEE; Généreux P, Piazza N, Alu MC, Nazif T, Hahn RT, Pibarot P, Bax JJ, Leipsic JA, Blanke P, Blackstone EH, Finn MT, Kapadia S, Linke A, Mack MJ, Makkar R, Mehran R, Popma JJ, Reardon M, Rodes-Cabau J, Van Mieghem NM, Webb JG, Cohen DJ, Leon MB. Valve Academic Research Consortium 3: updated endpoint definitions for aortic valve clinical research. *Eur Heart J.* 2021;42:1825-57.

13. Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. *Stat Med.* 2015;34:3661-79.

14. Benedetto U, Head SJ, Angelini GD, Blackstone EH. Statistical primer: propensity score matching and its alternatives. *Eur J Cardiothorac Surg.* 2018;53:1112-7.

15. Funk MJ, Westreich D, Wiesen C, Stürmer T, Brookhart MA, Davidian M. Doubly robust estimation of causal effects. *Am J Epidemiol.* 2011;173:761-7.

16. Mack MJ, Leon MB, Thourani VH, Makkar R, Kodali SK, Russo M, Kapadia SR, Malaisrie SC, Cohen DJ, Pibarot P, Leipsic J, Hahn RT, Blanke P, Williams MR, McCabe JM, Brown DL, Babaliaros V, Goldman S, Szeto WY, Genereux P, Pershad A, Pocock SJ, Alu MC, Webb JG, Smith CR; PARTNER 3 Investigators. Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients. *N Engl J Med.* 2019;380:1695-705.

17. Miyasaka M, Tada N, Taguri M, Kato S, Enta Y, Otomo T, Hata M, Watanabe Y, Naganuma T, Araki M, Yamanaka F, Shirai S, Ueno H, Mizutani K, Tabata M, Higashimori A, Takagi K, Yamamoto M, Hayashida K; OCEAN-TAVI Investigators. Incidence, Predictors, and Clinical Impact of Prosthesis-Patient Mismatch Following Transcatheter Aortic Valve Replacement in Asian Patients: The OCEAN-TAVI Registry. *JACC Cardiovasc Interv.* 2018;11:771-80.

18. Hase H, Yoshijima N, Yanagisawa R, Tanaka M, Tsuruta H, Shimizu H, Fukuda K, Naganuma T, Mizutani K, Yamawaki M, Tada N, Yamanaka F, Shirai S, Tabata M, Ueno H, Takagi K, Watanabe Y, Yamamoto M, Hayashida K; OCEAN-TAVI Investigators. Transcatheter aortic valve replacement with Evolut R versus Sapien 3 in Japanese patients with a small aortic annulus: The OCEAN-TAVI registry. *Catheter Cardiovasc Interv.* 2021;97:E875-86.

19. Schofer N, Deuschl F, Rübsamen N, Skibowski J, Seiffert M, Voigtländer L, Schaefer A, Schneeberger Y, Schirmer J, Reichenspurner H, Blankenberg S, Conradi L, Schäfer U. Prosthesis-patient mismatch after transcatheter aortic valve implantation: prevalence and prognostic impact with respect to baseline left ventricular function. *EuroIntervention.* 2019;14:1648-55.

20. Voigtländer L, Kim WK, Mauri V, Goßling A, Renker M, Sugiura A, Linder M, Schmidt T, Schofer N, Westermann D, Reichenspurner H, Nickenig G, Blankenberg S, Hamm C, Conradi L, Adam M, Sinning JM, Seiffert M. Transcatheter aortic valve implantation in patients with a small aortic annulus: performance of supra-, intra- and infra-annular transcatheter heart valves. *Clin Res Cardiol.* 2021;110:1957-66.

21. Tamburino C, Bleiziffer S, Thiele H, Scholtz S, Hildick-Smith D, Cunnington M, Wolf A, Barbanti M, Tchetchè D, Garot P, Pagnotta P, Gilard M, Bedogni F, Van Belle E, Vasa-Nicotera M, Chieffo A, Deutsch O, Kempfert J, Søndergaard L, Butter C, Trillo-Nouche R, Lotfi S, Möllmann H, Joner M, Abdel-Wahab M, Bogaerts K, Hengstenberg C, Capodanno D. Comparison of Self-Expanding Bioprostheses for Transcatheter Aortic Valve Replacement in Patients With Symptomatic Severe Aortic Stenosis: SCOPE 2 Randomized Clinical Trial. *Circulation.* 2020;142:2431-42.

22. Mauri V, Kim WK, Abumayyaleh M, Walther T, Moellmann H, Schaefer U, Conradi L, Hengstenberg C, Hilker M, Wahlers T, Baldus S, Rudolph V, Madershahian N, Rudolph TK. Short-Term Outcome and Hemodynamic Performance of Next-Generation Self-Expanding Versus Balloon-Expandable Transcatheter Aortic Valves in Patients With Small Aortic Annulus: A Multicenter Propensity-Matched Comparison. *Circ Cardiovasc Interv.* 2017 Oct;10:e005013.

23. Okuyama K, Izumo M, Ochiai T, Kuwata S, Kaihara T, Koga M, Kamijima R, Ishibashi Y, Tanabe Y, Higuma T, Makkar R, Miyairi T, Akashi YJ. New-Generation Transcatheter Aortic Valves in Patients With Small Aortic Annuli - Comparison of Balloon- and Self-Expandable Valves in Asian Patients. *Circ J.* 2020;84:2015-22.

24. Ternacle J, Guimaraes L, Vincent F, Côté N, Côté M, Lachance D, Clavel MA, Abbas AE, Pibarot P, Rodés-Cabau J. Reclassification of prosthesis-patient mismatch after transcatheter aortic valve replacement using predicted vs. measured indexed effective orifice area. *Eur Heart J Cardiovasc Imaging.* 2021;22:11-20.

25. Thiele H, Kurz T, Feistritzer HJ, Stachel G, Hartung P, Eitel I, Marquetand C, Nef H, Doerr O, Lauten A, Landmesser U, Abdel-Wahab M, Sandri M, Holzhey D, Borger M, Ince H, Öner A, Meyer-Saraei R, Wienbergen H, Fach A, Frey N, König IR, Vonthein R, Rückert Y, Funkat AK, de Waha-Thiele S, Desch S. Comparison of newer generation self-expandable vs. balloon-expandable valves in transcatheter aortic valve implantation: the randomized SOLVE-TAVI trial. *Eur Heart J.* 2020;41:1890-9.

26. Makkar RR, Cheng W, Waksman R, Satler LF, Chakravarty T, Groh M, Abernethy W, Russo MJ, Heimansohn D, Hermiller J, Worthley S, Chehab B, Cunningham M, Matthews R, Ramana RK, Yong G, Ruiz CE, Chen C, Asch FM, Nakamura M, Jilaihawi H, Sharma R, Yoon SH, Pichard AD, Kapadia S, Reardon MJ, Bhatt DL, Fontana GP. Self-expanding intra-annular versus commercially available transcatheter heart valves in high and extreme risk patients with severe aortic stenosis (PORTICO IDE): a randomised, controlled, non-inferiority trial. *Lancet.* 2020;396:669-83.

27. Möllmann H, Holzhey DM, Hilker M, Toggweiler S, Schäfer U, Treede H, Joner M, Søndergaard L, Christen T, Allocco DJ, Kim WK. The ACURATE *neo*2 valve system for transcatheter aortic valve implantation: 30-day and 1-year outcomes. *Clin Res Cardiol.* 2021;110:1912-20.

28. Pagnesi M, Jabbour RJ, Latib A, Kawamoto H, Tanaka A, Regazzoli D, Mangieri A, Montalto C, Ancona MB, Giannini F, Chieffo A, Montorfano M, Monaco F, Castiglioni A, Alfieri O, Colombo A. Usefulness of Predilation Before Transcatheter Aortic Valve Implantation. *Am J Cardiol.* 2016;118:107-12.

29. Lanz J, Kim WK, Walther T, Burgdorf C, Möllmann H, Linke A, Redwood S, Thilo C, Hilker M, Joner M, Thiele H, Conzelmann L, Conradi L, Kerber S, Schymik G, Prendergast B, Husser O, Stortecky S, Heg D, Jüni P, Windecker S, Pilgrim T; SCOPE I investigators. Safety and efficacy of a self-expanding versus a balloon-expandable bioprosthesis for transcatheter aortic valve replacement in patients with symptomatic severe aortic stenosis: a randomised non-inferiority trial. *Lancet.* 2019;394:1619-28.

Supplementary data

Supplementary Table 1. Baseline demographic characteristics according to prosthesis implanted.

Supplementary Table 2. Baseline echocardiographic and computed tomography characteristics according to prosthesis implanted.

Supplementary Table 3. Procedural characteristics according to prosthesis implanted.

Supplementary Table 4. Standardised mean differences (SMDs) of the covariates used for propensity score modelling before and after inverse probability of treatment weight (IPTW) adjustment.

Supplementary Table 5. Prediction of severe prosthesis-patient mismatch using doubly-robust inverse probability of treatment weight (IPTW)-adjusted logistic regression analysis.

Supplementary Table 6. Post-procedural characteristics and follow-up according to prosthesis implanted.

Supplementary Figure 1. Map of centres involved in the study.

Supplementary Figure 2. Incidence of severe and moderate PPM according to prosthesis type.

Supplementary Figure 3. Kaplan-Meier analysis assessing all-cause mortality according to prosthesis type.

The supplementary data are published online at: https://eurointervention.pcronline.com/doi/10.4244/EIJ-D-22-00843

Supplementary data

Supplementary Table 1. Baseline demographic characteristics according to prosthesis implanted.

Characteristic	Evolut R/Pro (n = 750)	Acurate Neo (n = 170)	Portico (n = 172)	Sapien 3 (n = 286)	P value
Age, years	83.0 ± 6.3	83.0 ± 5.8	82.7 ± 5.9	82.5 ± 6.5	0.689
Female	89.1 (668)	90.6 (154)	91.3 (157)	88.8 (254)	0.781
Weight, kg	63.2 ± 14.5	64.5 ± 12.9	66.2 ± 13.8	67.5 ± 16.4	**<0.001**
Height, cm	157.2 ± 7.8	157.8 ± 7.1	157.7 ± 6.0	159.1 ± 8.5	**0.009**
Body surface area, m^2	1.62 ± 0.21	1.66 ± 0.17	1.70 ± 0.19	1.71 ± 0.23	**<0.001**
Body mass index, kg/m^2	25.9 ± 5.5	26.1 ± 4.6	26.7 ± 5.2	26.5 ± 5.5	0.204
Hypertension	84.5 (633)	82.3 (140)	86.6 (149)	89.2 (255)	0.157
Diabetes mellitus	25.3 (190)	25.9 (44)	30.8 (53)	26.9 (77)	0.527
Dyslipidemia	53.9 (403)	50.0 (85)	50.3 (86)	48.4 (138)	0.396
COPD	10.3 (77)	14.1 (24)	6.4 (11)	16.1 (46)	**0.006**
Peripheral artery disease or previous PTA	13.7 (99)	8.2 (14)	10.0 (17)	9.5 (26)	**0.090**
Cerebrovascular disease	9.3 (70)	5.9 (10)	12.3 (21)	14.7 (42)	**0.012**
Previous PCI	20.4 (153)	19.4 (33)	27.5 (47)	23.9 (68)	0.149
Previous CABG	5.9 (44)	4.1 (7)	5.8 (10)	7.3 (21)	0.569
Previous MI	8.8 (65)	10.2 (16)	10.5 (18)	10.2 (29)	0.842

Coronary artery disease	37.0 (276)	31.2 (53)	36.3 (62)	46.8 (134)	**0.004**
PM or ICD	10.3 (77)	11.2 (19)	11.6 (20)	14.3 (41)	0.332
Atrial fibrillation	31.3 (143)	31.2 (39)	32.8 (43)	21.9 (44)	**0.066**
Angina	19.2 (132)	19.4 (33)	17.2 (20)	27.8 (45)	**0.075**
NYHA class III or IV	67.5 (506)	57.6 (98)	70.9 (122)	71.0 (203)	**0.019**
STS-PROM, %	6.0 ± 4.4	5.5 ± 3.8	5.1 ± 2.7	5.7 ± 3.6	**0.072**

Values are mean ± standard deviation or %(n). The values in **bold** represent differences between groups with p <0.100.

BAV = balloon aortic valvuloplasty; BMI = body mass index; BSA = body surface area; CABG = coronary artery bypass graft; CAD = coronary artery disease; COPD = chronic obstructive pulmonary disease; ICD = implantable cardioverter-defibrillator; MI = myocardial infarction; NT-proBNP = N-terminal pro–brain natriuretic peptide; NYHA = New York Heart Association; PTA = percutaneous transluminal angioplasty; PCI = percutaneous coronary intervention; PM = pacemaker; STS-PROM = Society of Thoracic Surgeons Predicted Risk of Mortality.

P values for Age

	Evolut R/Pro	**Acurate Neo**	**Portico**
Acurate Neo	1.000		
Portico	1.000	1.000	
Sapien 3	1.000	1.000	1.000

P values for Female

	Evolut R/Pro	**Acurate Neo**	**Portico**
Acurate Neo	0.561		
Portico	0.394	0.824	
Sapien 3	0.906	0.550	0.399

P values for BMI

	Evolut R/Pro	**Acurate Neo**	**Portico**
Acurate Neo	1.000		
Portico	0.489	1.000	
Sapien 3	0.573	1.000	1.000

P values for BSA

	Evolut R/Pro	**Acurate Neo**	**Portico**
Acurate Neo	0.868		
Portico	**0.001**	1.000	
Sapien 3	**<0.001**	0.656	1.000

P values for Weight

	Evolut R/Pro	**Acurate Neo**	**Portico**
Acurate Neo	1.000		
Portico	**0.098**	1.000	
Sapien 3	**<0.001**	0.208	1.000

P values for Diabetes Mellitus

	Evolut R/Pro	**Acurate Neo**	**Portico**
Acurate Neo	0.882		
Portico	0.141	0.312	
Sapien 3	0.601	0.808	0.371

P values for Dyslipidemia

	Evolut R/Pro	**Acurate Neo**	**Portico**
Acurate Neo	0.360		
Portico	0.397	0.957	
Sapien 3	0.117	0.744	0.699

P values for Hypertension

	Evolut R/Pro	**Acurate Neo**	**Portico**
Acurate Neo	0.487		
Portico	0.485	0.275	
Sapien 3	**0.055**	**0.039**	0.416

P values for COPD

	Evolut R/Pro	**Acurate Neo**	**Portico**
Acurate Neo	0.149		
Portico	0.123	**0.019**	
Sapien 3	**0.010**	0.573	**0.003**

P values for Peripheral artery disease or previous PTA

	Evolut R/Pro	**Acurate Neo**	**Portico**
Acurate Neo	**0.054**		
Portico	0.198	0.572	
Sapien 3	**0.076**	0.645	0.869

P values for Cerebrovascular disease

	Evolut R/Pro	**Acurate Neo**	**Portico**
Acurate Neo	0.149		
Portico	0.244	**0.040**	
Sapien 3	**0.013**	**0.004**	0.471

P values for Previous PCI

	Evolut R/Pro	**Acurate Neo**	**Portico**
Acurate Neo	0.760		
Portico	**0.044**	**0.079**	
Sapien 3	0.222	0.261	0.400

P values for Previous CABG

	Evolut R/Pro	**Acurate Neo**	**Portico**
Acurate Neo	0.365		
Portico	0.986	0.463	
Sapien 3	0.387	0.165	0.539

P values for Previous MI

	Evolut R/Pro	**Acurate Neo**	**Portico**
Acurate Neo	0.590		
Portico	0.489	0.921	
Sapien 3	0.505	0.996	0.905

P values for Coronary artery disease

	Evolut R/Pro	**Acurate Neo**	**Portico**
Acurate Neo	0.153		
Portico	0.856	0.321	
Sapien 3	**0.004**	**0.001**	**0.027**

P values for PM or ICD

	Evolut R/Pro	**Acurate Neo**	**Portico**
Acurate Neo	0.726		
Portico	0.600	0.896	
Sapien 3	**0.065**	0.335	0.409

P values for Atrial fibrillation

	Evolut R/Pro	**Acurate Neo**	**Portico**
Acurate Neo	0.984		
Portico	0.739	0.781	
Sapien 3	**0.014**	**0.061**	**0.027**

P values for Angina

	Evolut R/Pro	**Acurate Neo**	**Portico**
Acurate Neo	0.947		
Portico	0.621	0.643	
Sapien 3	**0.015**	**0.072**	**0.041**

P values for NYHA functional class III or IV

	Evolut R/Pro	**Acurate Neo**	**Portico**
Acurate Neo	**0.015**		
Portico	0.379	0.010	
Sapien 3	0.277	**0.004**	0.991

P values for STS-PROM

	Evolut R/Pro	**Acurate Neo**	**Portico**
Acurate Neo	1.000		
Portico	**0.079**	1.000	
Sapien 3	1.000	1.000	0.711

Supplementary Table 2. Baseline echocardiographic and computed tomography characteristics according to prosthesis implanted.

Characteristic	Evolut R/Pro (n = 750)	Acurate Neo (n = 170)	Portico (n = 172)	Sapien 3 (n = 286)	P value
Echocardiographic data					
Mean AV gradient, mmHg	48.7 ± 16.0	50.2 ± 16.8	46.8 ± 15.8	44.3 ± 15.3	**<0.001**
Maximum AV gradient, mmHg	80.0 ± 24.8	79.9 ± 24.7	74.0 ± 23.9	72.3 ± 24.4	**<0.001**
EOAm, cm^2	0.63 ± 0.18	0.66 ± 0.20	0.65 ± 0.22	0.67 ± 0.27	**0.048**
sPAP, mmHg	39.6 ± 13.4	39.6 ± 11.4	42.7 ± 14.8	41.5 ± 15.2	**0.077**
TAPSE	21.1 ± 3.9	20.8 ± 3.2	20.6 ± 3.0	20.0 ± 2.9	0.181
Bicuspid AV	3.7 (20)	2.5 (4)	3.6 (6)	7.3 (19)	**0.055**
Moderate or greater AR	7.9 (52)	10.2 (15)	4.3 (7)	3.4 (9)	**0.018**
Moderate or greater MR	10.2 (71)	11.0 (17)	10.2 (17)	2.6 (7)	**0.001**
Moderate or greater TR	8.8 (47)	5.0 (7)	6.7 (11)	3.8 (9)	**0.060**
Ejection fraction	58.5 ± 11.1	56.5 ± 9.6	59.9 ± 9.2	62.2 ± 10.2	**<0.001**
LVEF <40%	6.0 (45)	6.5 (11)	3.5 (6)	3.1 (9)	0.169
CT data					
Mean annular diameter, mm	21.1 ± 1.4	21.5 ± 1.3	21.2 ± 1.3	21.4 ± 1.0	**<0.001**
Maximum diameter, mm	23.6 ± 1.9	23.7 ± 1.8	23.9 ± 1.8	24.0 ± 1.4	**0.007**
Minimum diameter, mm	18.7 ± 1.9	19.3 ± 1.9	18.4 ± 1.6	18.9 ± 1.5	**<0.001**
Annular eccentricity	1.27 ± 0.17	1.24 ± 0.15	1.30 ± 0.16	1.28 ± 0.18	**0.010**
Mean aortic annular perimeter, mm	67.3 ± 3.7	67.4 ± 3.3	67.6 ± 3.4	65.0 ± 5.9	**<0.001**
Mean aortic annular area, mm^2	345.6 ± 35.3	352.6 ± 36.0	343.8 ± 33.1	362.3 ± 28.7	**<0.001**
Area-derived diameter, mm	20.9 ± 1.1	21.2 ± 1.1	20.9 ± 1.0	21.5 ± 0.9	**<0.001**

Perimeter-derived diameter, mm	21.4 ± 1.2	21.5 ± 1.0	21.5 ± 1.2	20.7 ± 1.9	**<0.001**
Severe leaflets calcification	18.1 (88)	20.6 (19)	8.6 (8)	24.5 (70)	**0.005**
Severe annular calcification	6.0 (24)	7.5 (5)	3.5 (5)	1.5 (4)	**0.015**
Severe LVOT calcification	5.8 (30)	5.1 (4)	2.1 (2)	1.4 (4)	**0.009**
LMCA distance, mm	12.5 ± 2.5	11.7 ± 2.5	12.0 ± 2.8	12.8 ± 2.6	**<0.001**
RCA distance, mm	14.4 ± 2.9	13.5 ± 3.2	14.5 ± 2.6	14.7 ± 2.5	**0.006**
Sinotubular junction diameter, mm	25.7 ± 2.7	26.1 ± 3.1	26.3 ± 2.7	25.9 ± 2.4	0.119
Sinus of Valsalva diameter, mm	28.8 ± 2.5	29.1 ± 2.9	29.0 ± 2.4	28.4 ± 2.5	**0.053**
Ascending aorta diameter, mm	31.5 ± 3.8	32.3 ± 4.1	32.8 ± 4.3	32.0 ± 3.8	**0.007**
Porcelain aorta	2.7 (17)	2.5 (4)	5.4 (9)	11.9 (31)	**<0.001**

Values are mean ± standard deviation or %(n). The values in **bold** represent differences between groups with p <0.100.
AV = aortic valve; AR = aortic regurgitation; EOA = effective orifice area; LMCA = left main coronary artery; LVEF = left ventricular ejection fraction; LVEDV = left ventricular end systolic volume; LVESV = left ventricular end systolic volume; LVOT = left ventricular outflow tract; MDCT = multidetector computed tomographic; MR = mitral regurgitation; sPAP = systolic pulmonary artery pressure; RCA = right coronary artery; RV = right ventricular; TR = tricuspid regurgitation; other abbreviations as in **Supplementary Table 1**.

P values for pre-procedural mean aortic valve gradient

	Evolut R/Pro	**Acurate Neo**	**Portico**
Acurate Neo	1.000		
Portico	0.954	0.307	
Sapien 3	**0.001**	**0.001**	0.692

P values for pre-procedural maximum aortic valve gradient

	Evolut R/Pro	**Acurate Neo**	**Portico**
Acurate Neo	1.000		
Portico	**0.040**	0.221	
Sapien 3	**<0.001**	**0.014**	1.000

P values for EOAm

	Evolut R/Pro	**Acurate Neo**	**Portico**
Acurate Neo	0.796		
Portico	1.000	1.000	
Sapien 3	**0.061**	1.000	1.000

P values for sPAP

	Evolut R/Pro	**Acurate Neo**	**Portico**
Acurate Neo	1.000		
Portico	0.154	0.480	
Sapien 3	0.583	1.000	1.000

P values for TAPSE

	Evolut R/Pro	**Acurate Neo**	**Portico**
Acurate Neo	1.000		
Portico	1.000	1.000	
Sapien 3	0.216	1.000	1.000

P values for Bicuspid aorta

	Evolut R/Pro	**Acurate Neo**	**Portico**
Acurate Neo	0.481		
Portico	0.943	0.586	
Sapien 3	**0.025**	**0.037**	0.106

P values for Moderate or greater AR

	Evolut R/Pro	**Acurate Neo**	**Portico**
Acurate Neo	0.353		
Portico	0.121	**0.046**	
Sapien 3	**0.015**	**0.005**	0.638

P values for Moderate or greater MR

	Evolut R/Pro	**Acurate Neo**	**Portico**
Acurate Neo	0.790		
Portico	0.999	0.833	
Sapien 3	**<0.001**	**<0.001**	**0.001**

P values for Moderate or greater TR

	Evolut R/Pro	**Acurate Neo**	**Portico**
Acurate Neo	0.141		
Portico	0.386	0.540	
Sapien 3	**0.013**	0.572	0.192

P values for Ejection fraction

	Evolut R/Pro	**Acurate Neo**	**Portico**
Acurate Neo	0.189		
Portico	0.641	**0.019**	
Sapien 3	**<0.001**	**<0.001**	0.133

P values for LVEF <40%

	Evolut R/Pro	**Acurate Neo**	**Portico**
Acurate Neo	0.817		
Portico	0.194	0.205	
Sapien 3	**0.065**	**0.094**	0.842

P values for mean aortic annulus diameter

	Evolut R/Pro	**Acurate Neo**	**Portico**
Acurate Neo	**0.014**		
Portico	1.000	0.123	
Sapien 3	**0.006**	1.000	0.151

P values for maximum aortic annulus diameter

	Evolut R/Pro	**Acurate Neo**	**Portico**
Acurate Neo	1.000		
Portico	0.287	1.000	
Sapien 3	**0.006**	0.790	1.000

P values for minimum aortic annulus diameter

	Evolut R/Pro	**Acurate Neo**	**Portico**
Acurate Neo	**0.002**		
Portico	0.533	**<0.001**	
Sapien 3	0.725	0.208	**0.052**

P values for Mean aortic annular area

	Evolut R/Pro	**Acurate Neo**	**Portico**
Acurate Neo	0.110		
Portico	1.000	0.107	
Sapien 3	**<0.001**	**0.021**	**<0.001**

P values for Mean aortic annular perimeter

	Evolut R/Pro	**Acurate Neo**	**Portico**
Acurate Neo	1.000		
Portico	1.000	1.000	
Sapien 3	**<0.001**	**<0.001**	**<0.001**

P values for LMCA distance

	Evolut R/Pro	**Acurate Neo**	**Portico**
Acurate Neo	**0.035**		
Portico	0.285	1.000	
Sapien 3	0.541	**0.001**	**0.014**

P values for RCA distance

	Evolut R/Pro	**Acurate Neo**	**Portico**
Acurate Neo	**0.040**		
Portico	1.000	**0.081**	
Sapien 3	0.980	**0.003**	1.000

P values for Sinotubular junction diameter

	Evolut R/Pro	**Acurate Neo**	**Portico**
Acurate Neo	1.000		
Portico	0.154	1.000	
Sapien 3	1.000	1.000	0.997

P values for Sinus of Valsalva diameter

	Evolut R/Pro	**Acurate Neo**	**Portico**
Acurate Neo	1.000		
Portico	1.000	1.000	
Sapien 3	0.322	0.205	0.170

P values for Ascending aorta diameter

	Evolut R/Pro	**Acurate Neo**	**Portico**
Acurate Neo	0.658		
Portico	**0.006**	1.000	
Sapien 3	0.752	1.000	0.296

P values for Porcelain aorta

	Evolut R/Pro	**Acurate Neo**	**Portico**
Acurate Neo	1.000		
Portico	**0.081**	0.259	
Sapien 3	**<0.001**	**<0.001**	**0.026**

P values for Area-derived diameter

	Evolut R/Pro	**Acurate Neo**	**Portico**
Acurate Neo	0.117		
Portico	1.000	0.124	
Sapien 3	**<0.001**	**0.020**	**<0.001**

P values for Perimeter-derived diameter

	Evolut R/Pro	**Acurate Neo**	**Portico**
Acurate Neo	1.000		
Portico	1.000	1.000	
Sapien 3	**<0.001**	**<0.001**	**<0.001**

P values for Severe leaflets calcification

	Evolut R/Pro	**Acurate Neo**	**Portico**
Acurate Neo	0.558		
Portico	**0.024**	**0.020**	
Sapien 3	**0.033**	0.452	**0.001**

P values for Severe annular calcification

	Evolut R/Pro	**Acurate Neo**	**Portico**
Acurate Neo	0.587		
Portico	0.384	0.297	
Sapien 3	**0.005**	**0.020**	0.288

P values for Severe LVOT calcification

	Evolut R/Pro	**Acurate Neo**	**Portico**
Acurate Neo	1.000		
Portico	0.209	0.410	
Sapien 3	**0.003**	**0.070**	0.646

P values for Annular eccentricity

	Evolut R/Pro	**Acurate Neo**	**Portico**
Acurate Neo	0.196		
Portico	0.211	**0.005**	
Sapien 3	1.000	0.125	0.874

Supplementary Table 3. Procedural characteristics according to prosthesis implanted.

Characteristic	Evolut R/Pro (n = 750)	Acurate Neo (n = 170)	Portico (n = 172)	Sapien 3 (n = 286)	P value
Valve size 25 mm or less	16.1 (121)	95.3 (162)	88.9 (153)	98.9 (283)	**<0.001**
Oversizing by perimeter	19.2 ± 6.3	9.7 ± 5.8	14.1 ± 5.8	9.5 ± 11.4	**<0.001**
Oversizing by perimeter ≥15%	75.5 (566)	14.7 (25)	43.6 (75)	27.6 (79)	**<0.001**
Oversizing by area	50.4 ± 16.0	25.4 ± 12.8	39.4 ± 13.3	11.9 ± 9.4	**<0.001**
Oversizing by area ≥15%	99.6 (747)	81.8 (139)	98.8 (170)	28.7 (82)	**<0.001**
Oversizing ≥15%	75.5 (566)	14.7 (25)	43.6 (75)	28.7 (82)	**<0.001**
Pre-dilation	33.6 (250)	65.7 (111)	70.0 (120)	32.9 (92)	**<0.001**
Post-dilation	30.8 (230)	36.5 (62)	38.2 (65)	8.2 (23)	**<0.001**
Annular rupture	0.3 (2)	0	0.6 (1)	0.3 (1)	0.826

Values are mean ± standard deviation or %(n). The values in **bold** represent differences between groups with p <0.100. Oversizing ≥15% refers to oversizing by perimeter ≥15% for self-expandable valves and oversizing by area ≥15% for balloon-expandable valves.

P values for Valve size 25 mm or less

	Evolut R/Pro	Acurate Neo	Portico
Acurate Neo	**<0.001**		
Portico	**<0.001**	**0.030**	
Sapien 3	**<0.001**	**0.023**	**<0.001**

P values for Oversizing by perimeter ≥15%

	Evolut R/Pro	Acurate Neo	Portico
Acurate Neo	**<0.001**		
Portico	**<0.001**	**<0.001**	
Sapien 3	**<0.001**	**0.001**	**<0.001**

P values for Oversizing by perimeter

	Evolut R/Pro	**Acurate Neo**	**Portico**
Acurate Neo	**<0.001**		
Portico	**<0.001**	**<0.001**	
Sapien 3	**<0.001**	1.000	**<0.001**

P values for Oversizing by area ≥15%

	Evolut R/Pro	**Acurate Neo**	**Portico**
Acurate Neo	**<0.001**		
Portico	0.235	**<0.001**	
Sapien 3	**<0.001**	**<0.001**	**<0.001**

P values for Oversizing by area

	Evolut R/Pro	**Acurate Neo**	**Portico**
Acurate Neo	**<0.001**		
Portico	**<0.001**	**<0.001**	
Sapien 3	**<0.001**	**<0.001**	**<0.001**

P values for Oversizing ≥15%

	Evolut R/Pro	**Acurate Neo**	**Portico**
Acurate Neo	**<0.001**		
Portico	**<0.001**	**<0.001**	
Sapien 3	**<0.001**	**0.001**	**0.001**

P values for Predilation

	Evolut R/Pro	**Acurate Neo**	**Portico**
Acurate Neo	**<0.001**		
Portico	**<0.001**	0.420	
Sapien 3	0.832	**<0.001**	**<0.001**

P values for Postdilation

	Evolut R/Pro	**Acurate Neo**	**Portico**
Acurate Neo	0.154		
Portico	**0.062**	0.737	
Sapien 3	**<0.001**	**<0.001**	**<0.001**

P values for Annular rupture

	Evolut R/Pro	**Acurate Neo**	**Portico**
Acurate Neo	1.000		
Portico	0.481	1.000	
Sapien 3	1.000	1.000	1.000

Supplementary Table 4. Standardised mean differences (SMDs) of the covariates used for propensity score modelling before and after inverse probability of treatment weight (IPTW) adjustment.

Covariates	SAV vs. IAV		SEV vs. BEV	
	Before adjustment	After adjustment	Before adjustment	After adjustment
Age	17.0	-0.4	14.8	1.2
BMI	-9.6	0.8	0.2	8.4
Female	8.6	0.9	3.6	1.6
Hypertension	-7.2	-0.3	-5.6	2.4
COPD	-4.3	-0.6	-16.4	1.7
Cerebrovascular disease	-18.8	-0.4	-19.5	1.8
CAD	-13.3	-0.04	-20.1	1.5
Previous PM/ICD	-16.9	-0.4	-19.2	2.3
NYHA Class III/IV	-9.6	-0.5	-2.1	1.9
STS-PROM	3.2	-0.7	-6.3	-2.3
Preprocedural mean AV gradient	15.7	1.2	1.6	4.4
LVEF	-21.2	2.7	-28.2	7.4
AV annular perimeter	36.8	-1.0	61.0	-11.2

Values are in %. Abbreviations as in Supplementary Table 5.

Supplementary Table 5. Prediction of severe prosthesis-patient mismatch using doubly-robust inverse probability of treatment weight (IPTW)-adjusted logistic regression analysis.

SAV vs. IAV		
Clinical characteristics	**Doubly-robust IPTW-adjusted OR (95% CI)**	**P value**
Atrial fibrillation	0.33 (0.13-0.88)	**0.027**
Annular perimeter, mm	0.25 (0.10-0.61)	**0.003**
Bicuspid AV	0.27 (0.11-0.65)	**0.004**
Moderate/severe AV leaflet calcification	0.28 (0.11-0.72)	**0.008**
Any AV annular calcification	0.32 (0.12-0.85)	**0.022**
Any LVOT calcification	0.30 (0.11-0.83)	**0.021**
SEV vs. BEV		
Clinical characteristics	**Doubly-robust IPTW-adjusted OR (95% CI)**	**P value**
Atrial fibrillation	0.44 (0.18-1.08)	**0.073**
Annular perimeter, mm	0.40 (0.17-0.91)	**0.029**
Bicuspid AV	0.40 (0.17-0.92)	**0.031**
Moderate/severe AV leaflet calcification	0.37 (0.15-0.90)	**0.029**
Any AV annular calcification	0.46 (0.19-1.10)	**0.080**
Any LVOT calcification	0.42 (0.16-1.07)	**0.070**

AV = aortic valve; BEV = balloon-expandable valve; CI = confidence interval; IAV = intra-annular valve; IPTW = inverse probability of treatment weighting; LVOT = left ventricular outflow tract; SAV = supra-annular valve; SEV = self-expandable valve.
The values in bold represent differences between groups with $p < 0.100$.

Supplementary Table 6. Post-procedural characteristics and follow-up according to prosthesis implanted.

Characteristic	Evolut R/Pro (n = 750)	Acurate Neo (n = 170)	Portico (n = 172)	Sapien 3 (n = 286)	P value
Pre-discharge					
Any vascular complication	12.1 (90)	20.2 (34)	17.4 (30)	13.3 (38)	**0.025**
Major vascular complication	4.0 (30)	5.9 (10)	5.2 (9)	5.6 (16)	0.598
Need for second valve implantation	2.1 (16)	0	3.5 (6)	0.3 (1)	**0.009**
Mean AV gradient, mmHg	7.5 ± 3.8	8.7 ± 4.4	9.2 ± 4.5	13.6 ± 4.7	**<0.001**
Maximum AV gradient, mmHg	14.1 ± 6.4	16.3 ± 8.2	17.1 ± 9.0	24.8 ± 7.7	**<0.001**
EOA, cm^2	1.71 ± 0.48	1.91± 0.58	1.63 ± 0.43	1.41 ± 0.29	**<0.001**
Indexed EOA, cm^2/m^2	1.09 ± 0.30	1.18 ± 0.36	0.97 ± 0.28	0.84 ± 0.19	**<0.001**
Any PPM (non BMI-adjusted)	17.1 (47)	15.5 (9)	35.9 (28)	58.3 (127)	**<0.001**
Any PPM	14.4 (36)	13.8 (8)	29.5 (23)	49.5 (108)	**<0.001**
Moderate PPM (non BMI-adjusted)	13.1 (36)	10.3 (6)	24.4 (19)	44.0 (96)	**<0.001**
Moderate PPM	9.8 (27)	10.3 (6)	20.5 (16)	40.8 (89)	**<0.001**
Severe PPM (non BMI-adjusted)	4.0 (11)	5.2 (3)	11.5 (9)	14.2 (31)	**<0.001**
Severe PPM	3.6 (10)	3.4 (2)	9.0 (7)	8.7 (19)	**0.058**
More than mild PVL	9.9 (58)	11.2 (15)	19.0 (27)	2.6 (7)	**<0.001**
More than moderate PVL	0.8 (5)	4.5 (6)	0.7 (1)	0	**0.002**
PPI	13.9 (103)	10.2 (17)	15.1 (26)	8.1 (23)	**0.039**

BARC major bleeding	6.9 (52)	4.1 (7)	2.9 (5)	5.9 (17)	0.166
Follow-up					
All-cause mortality	9.8 (65)	7.9 (11)	11.2 (19)	12.3 (34)	0.482
Cardiovascular mortality	2.7 (18)	2.9 (4)	5.4 (9)	4.0 (11)	0.332
Myocardial infarction	1.0 (6)	0.8 (1)	2.7 (3)	0.7 (2)	0.367
TIA/stroke	4.4 (26)	1.5 (2)	1.3 (1)	2.6 (7)	0.254
Acute kidney injury	2.4 (12)	8.1 (7)	4.8 (3)	1.9 (5)	**0.020**
Hospitalization for HF	6.0 (35)	5.3 (7)	7.8 (6)	6.6 (17)	0.896

Values are mean ± standard deviation or %(n). The values in **bold** represent differences between groups with p <0.100. BARC = Bleeding Academic Research Consortium; HF = heart failure; PPM = prosthesis patient mismatch; PPI = permanent pacemaker implantation; PVL = paravalvular leak; TIA = transient ischemic attack; other abbreviations as in **Tables 1** and **2**.

P values for Any vascular complication

	Evolut R/Pro	**Acurate Neo**	**Portico**
Acurate Neo	**0.006**		
Portico	**0.064**	0.510	
Sapien 3	0.620	**0.050**	0.226

P values for Major vascular complication

	Evolut R/Pro	**Acurate Neo**	**Portico**
Acurate Neo	0.277		
Portico	0.489	0.773	
Sapien 3	0.283	0.874	0.869

P values for Need of second valve implantation

	Evolut R/Pro	**Acurate Neo**	**Portico**
Acurate Neo	**0.054**		
Portico	0.296	**0.030**	
Sapien 3	**0.053**	1.000	**0.013**

P values for post-procedural mean aortic valve gradient

	Evolut R/Pro	**Acurate Neo**	**Portico**
Acurate Neo	**0.020**		
Portico	**<0.001**	1.000	
Sapien 3	**<0.001**	**<0.001**	**<0.001**

P values for post-procedural maximal aortic valve gradient

	Evolut R/Pro	**Acurate Neo**	**Portico**
Acurate Neo	**0.007**		
Portico	**0.003**	1.000	
Sapien 3	**<0.001**	**<0.001**	**<0.001**

P values for post-procedural EOA

	Evolut R/Pro	**Acurate Neo**	**Portico**
Acurate Neo	**0.006**		
Portico	0.860	**0.001**	
Sapien 3	**<0.001**	**<0.001**	**<0.001**

P values for post-procedural EOAi

	Evolut R/Pro	**Acurate Neo**	**Portico**
Acurate Neo	0.166		
Portico	**0.004**	**<0.001**	
Sapien 3	**<0.001**	**<0.001**	**0.002**

P values for any non BMI-adjusted PPM

	Evolut R/Pro	**Acurate Neo**	**Portico**
Acurate Neo	0.762		
Portico	**<0.001**	**0.008**	
Sapien 3	**<0.001**	**<0.001**	**0.001**

P values for any PPM

	Evolut R/Pro	**Acurate Neo**	**Portico**
Acurate Neo	0.953		
Portico	**0.001**	**0.031**	
Sapien 3	**<0.001**	**<0.001**	**0.002**

P values for moderate non BMI-adjusted PPM

	Evolut R/Pro	**Acurate Neo**	**Portico**
Acurate Neo	0.561		
Portico	**0.016**	**0.037**	
Sapien 3	**<0.001**	**<0.001**	**0.002**

P values for moderate PPM

	Evolut R/Pro	**Acurate Neo**	**Portico**
Acurate Neo	0.910		
Portico	**0.011**	0.111	
Sapien 3	**<0.001**	**<0.001**	**0.001**

P values for severe non BMI-adjusted PPM

	Evolut R/Pro	**Acurate Neo**	**Portico**
Acurate Neo	0.718		
Portico	**0.011**	0.235	
Sapien 3	**<0.001**	**0.072**	0.700

P values for severe PPM

	Evolut R/Pro	**Acurate Neo**	**Portico**
Acurate Neo	1.000		
Portico	**0.053**	0.300	
Sapien 3	**0.018**	0.265	0.945

P values for PPI

	Evolut R/Pro	**Acurate Neo**	**Portico**
Acurate Neo	0.200		
Portico	0.680	0.172	
Sapien 3	**0.011**	0.446	**0.018**

P values for more than moderate PVL

	Evolut R/Pro	**Acurate Neo**	**Portico**
Acurate Neo	**0.008**		
Portico	1.000	**0.060**	
Sapien 3	0.332	**0.001**	0.346

P values for more than mild PVL

	Evolut R/Pro	**Acurate Neo**	**Portico**
Acurate Neo	0.645		
Portico	**0.002**	**0.071**	
Sapien 3	**<0.001**	**<0.001**	**<0.001**

P values for BARC major bleeding

	Evolut R/Pro	**Acurate Neo**	**Portico**
Acurate Neo	0.176		
Portico	**0.053**	0.572	
Sapien 3	0.568	0.517	0.178

P values for All-cause mortality

	Evolut R/Pro	**Acurate Neo**	**Portico**
Acurate Neo	0.478		
Portico	0.575	0.317	
Sapien 3	0.250	0.166	0.734

P values for Cardiovascular mortality

	Evolut R/Pro	**Acurate Neo**	**Portico**
Acurate Neo	1.000		
Portico	**0.024**	0.141	
Sapien 3	0.317	0.782	0.473

P values for Myocardial infarction

	Evolut R/Pro	**Acurate Neo**	**Portico**
Acurate Neo	1.000		
Portico	0.160	0.346	
Sapien 3	1.000	1.000	0.143

P values for TIA/stroke

	Evolut R/Pro	**Acurate Neo**	**Portico**
Acurate Neo	0.140		
Portico	0.348	1.000	
Sapien 3	0.195	0.724	1.000

P values for Acute kidney injury

	Evolut R/Pro	**Acurate Neo**	**Portico**
Acurate Neo	**0.005**		
Portico	0.220	0.521	
Sapien 3	0.799	**0.011**	0.176

P values for Hospitalization for HF

	Evolut R/Pro	**Acurate Neo**	**Portico**
Acurate Neo	0.775		
Portico	0.538	0.481	
Sapien 3	0.751	0.636	0.708

Supplementary Figure 1. Map of centres involved in the study.



Supplementary Figure 2. Incidence of severe and moderate PPM according to prosthesis type.



Supplementary Figure 3. Kaplan-Meier analysis assessing all-cause mortality according to prosthesis type.